← Leaderboards
Linda J. Burns
University Of Minnesota Twin Cities
$287,440
Attributed
$431,769
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $288.7K · FY2005–13$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$431,769 · 15
By mechanism
R25$288,658 · 1
M01$93,111 · 13
R13$50,000 · 1
Top collaborators
- Lillian Sung1 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Morayma Reyes$420,958
- Bernhard Josef Hering$29,197,217
- R Scott McIvor$12,592,678
- Alexander M McBean$1,902,455
- Bianca M Conti-Fine$5,252,354
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantResourcesResearch PersonnelInstitutionFundingSourceComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthLabelUpper ArmClinical ResearchSafetyDoseBiodistributionAllogenicHuman Anti-Mouse AntibodyPtprc GeneAntibody FormationLymphomaRefractoryHematopoietic Stem CellsProspectiveMineralsPrevent
Grant awards (15)
Training and Mentorship of Hematologic Oncologists$288,658
R25 · FY2013 · CA · contact PI
MT2005-06-A RANDOMIZED PHASE II STUDY OF ZOLENDRONIC ACID (ZOMETA) IN THE PREVEN$7,318
M01 · FY2009 · RR · contact PI
2008 Clinical Research Training Institute Summer Workshop$50,000
R13 · FY2008 · HL · contact PI
MT2005-14-PHASE I OPEN LABEL, SINGLE ARM, DOSE ESCALATION TRIAL TO EVALUATE THE$8,481
M01 · FY2008 · RR · contact PI
MT2005-06-A RANDOMIZED PHASE II STUDY OF ZOLENDRONIC ACID (ZOMETA) IN THE PREVEN$8,392
M01 · FY2008 · RR · contact PI
MT2005-13-A PHASE I OPEN LABEL, SINGLE ARM, DOSE ESCALATION TRIAL TO EVALUATE TH$1,281
M01 · FY2008 · RR · contact PI
MT2005-06-A RANDOMIZED PHASE II STUDY OF ZOLENDRONIC ACID (ZOMETA) IN THE PREVEN$10,100
M01 · FY2007 · RR · contact PI
MT2005-13-PHASE I OPEN LABEL, SINGLE ARM, DOSE ESCALATION TRIAL TO EVALUATE THE$4,340
M01 · FY2007 · RR · contact PI
MT2005-14-A PHASE I OPEN LABEL, SINGLE ARM, DOSE ESCALATION TRIAL TO EVALUATE TH$3,067
M01 · FY2007 · RR · contact PI
MT-2002-05-POST-TRANSPLANT IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL-2) AND RITUXIMAB$2,413
M01 · FY2007 · RR · contact PI
POST-TRANSPLANT IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL-2) AND RITUXIMAB$6,402
M01 · FY2006 · RR · contact PI
A PHASE I OPEN LABEL, SINGLE ARM, DOSE ESCALATION TRIAL TO EVALUATE THE BIODISTR$3,156
M01 · FY2006 · RR · contact PI
POST-TRANSPLANT IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL-2) AND RITUXIMAB$9,976
M01 · FY2005 · RR
A PHASE I STUDY OF AHN-12 IN PATIENTS WITH ADVANCED LEUKEMIA/LYMPHOMA$5,673
M01 · FY2005 · RR
Post-Transplant Immunotherapy with Interleukin-2 (IL-2) and Rituximab$22,512
M01 · FY2004 · RR